XWELL (XWEL)
NASDAQ:XWEL
Want to see XWEL full AI Analyst Report?
Top Page
XWELL
(NASDAQ:XWEL)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▲(100.00% Upside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by very weak financial performance (large losses, declining revenue, negative free cash flow, and high leverage). Technical momentum is a notable offset with the stock trading above major moving averages and positive MACD, while the recent financing improves liquidity but comes with meaningful dilution risk and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Location-based, convenience health model
Operating in airports and other high-traffic venues gives XWELL durable access to captive, convenience-driven customers and travel-related demand. This footprint supports steady walk-in volume and partnership opportunities with travel and enterprise clients, providing a repeatable revenue base despite cyclical trends.
Negative Factors
Deep trailing losses
Net margin near -81% reflects structural unprofitability that erodes equity and requires sustained operational change or sizable revenue gains to reverse. Persistent heavy losses increase dependence on external capital and heighten the risk that near-term operational improvements will be insufficient to restore self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Location-based, convenience health model
Operating in airports and other high-traffic venues gives XWELL durable access to captive, convenience-driven customers and travel-related demand. This footprint supports steady walk-in volume and partnership opportunities with travel and enterprise clients, providing a repeatable revenue base despite cyclical trends.
Read all positive factors
XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.56M
Dividend YieldN/A
Average Volume (3M)79.79K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth-10.46%
EPS Growth-41.03%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)-5.59
Shares Outstanding8,444,266
10 Day Avg. Volume196,854
30 Day Avg. Volume79,787
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.12
Price to Sales (P/S)0.09
P/FCF Ratio-0.22
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-0.12
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XWELL Business Overview & Revenue Model
Company Description
XWELL Inc., a health and wellness services company, provides spa services at airports. It operates through XpresSpa, XpresTest, Treat, and HyperPointe brands. The company offers spa services, including massage, and nail and skin care, as well as s...
How the Company Makes Money
XWELL’s revenue is generated primarily by providing fee-based health and wellness services directly to customers and, where applicable, to enterprise or institutional clients. Key revenue streams have included: (1) on-site, in-person services deli...
XWELL Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Read all positive updates
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.XWELL Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 29.21M | 33.90M | 30.11M | 55.94M | 73.73M |
| Gross Profit | 7.51M | 8.92M | 3.68M | 12.05M | 32.34M |
| EBITDA | -14.16M | -11.16M | -15.75M | -19.12M | 8.14M |
| Net Income | -16.99M | -16.85M | -27.74M | -32.84M | 3.35M |
Balance Sheet | |||||
| Total Assets | 11.22M | 25.35M | 38.99M | 70.43M | 127.27M |
| Cash, Cash Equivalents and Short-Term Investments | 2.62M | 11.80M | 23.05M | 42.19M | 105.51M |
| Total Debt | 12.49M | 10.77M | 11.09M | 14.11M | 13.82M |
| Total Liabilities | 23.80M | 17.61M | 18.02M | 22.48M | 27.33M |
| Stockholders Equity | -22.04M | -788.00K | 13.00M | 39.93M | 92.73M |
Cash Flow | |||||
| Free Cash Flow | -11.68M | -12.80M | -18.45M | -31.02M | 6.97M |
| Operating Cash Flow | -8.71M | -11.01M | -16.07M | -24.19M | 14.56M |
| Investing Cash Flow | 4.33M | 5.89M | 5.65M | -34.84M | -5.16M |
| Financing Cash Flow | 1.94M | 1.36M | 8.00K | -27.38M | 6.35M |
XWELL Technical Analysis
Neutral
0.50
Price Trends
1.28
Negative
1.00
Positive
0.96
Positive
Market Momentum
0.03
Positive
43.62
Neutral
12.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Neutral. The current price of 0.5 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.28, and below the 200-day MA of 0.96, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 43.62 is Neutral, neither overbought nor oversold. The STOCH value of 12.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XWELL Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $70.57M | 0.64 | 59.91% | ― | 14.95% | 29.24% | |
58 Neutral | $9.01M | 24.42 | 48.22% | ― | 13.70% | ― | |
52 Neutral | $139.32M | -6.89 | -9.68% | ― | -36.31% | -184.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.56M | -0.39 | 357.74% | ― | -10.46% | -41.03% | |
| ― | $4.93M | 0.02 | -1.53% | ― | -1.57% | ― | |
44 Neutral | $1.87M | ― | -233.76% | ― | 140.26% | 99.95% |
* Healthcare Sector Average
XWEL
XWELL
1.25
0.28
28.87%
MED
Medifast
12.53
-0.79
-5.93%
RGS
Regis
28.24
5.97
26.81%
MRM
MEDIROM Healthcare Technologies
1.14
-0.37
-24.50%
EJH
E-Home Household Service Holdings
1.54
-77.71
-98.06%
TRNR
Interactive Strength Inc
0.80
-86.70
-99.08%
XWELL Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
XWELL Completes Major Series H Financing and Restructuring
Positive
Mar 4, 2026
On February 24, 2026, XWELL, Inc. entered into a securities purchase agreement with an accredited investor for a private placement of Series H Convertible Preferred Stock and common stock warrants, with initial closings completed on February 27 an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.